SSY Group's (HKG:2005) SYN045 tablets, a PGI2 receptor agonist, obtained approval from China's National Medical Products Administration for adding three different specifications for a phase I clinical trial, a Thursday Hong Kong bourse filing said.

The indications will help meet the diversified needs of clinical trials, achieve dose gradient for patients of different age groups, further optimize precise dosing regimen, and boost the clinical application value of the tablets.